secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001437749-24-005127
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar announces promising preclinical data for MNPR-101 radiopharma; Phase 1 trial in Australia cleared
--------------------------------------------------------------------------------

- MNPR-101 targets uPAR, expressed in majority of triple-negative breast, colorectal, and pancreatic cancers.
- Optimized MNPR-101-Zr imaging agent shows increased tumor uptake and reduced healthy tissue uptake in PET studies.
- Single injection of MNPR-101 conjugated to Ac-225 or other therapeutic isotope led to near complete tumor elimination in mouse models.
- Received HREC clearance in Australia to start Phase 1 dosimetry trial of MNPR-101-Zr in advanced cancer patients.
- Company plans to present results at an upcoming scientific meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924005127/0001437749-24-005127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924005127/mnpr20240221_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-005127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer